Hepatic Arterial Infusion Chemotherapy with Cisplatin versus Sorafenib for Intrahepatic Advanced Hepatocellular Carcinoma: A Propensity Score-Matched Analysis

Hepatic Arterial Infusion Chemotherapy with Cisplatin versus Sorafenib for Intrahepatic Advanced Hepatocellular Carcinoma: A Propensity Score-Matched Analysis

Given that the outcome of hepatic arterial infusion chemotherapy (HAIC) with cisplatin for intrahepatic advanced hepatocellular carcinoma (HCC) is unclear, we aimed to compare prognostic factors for overall survival (OS) following HAIC with cisplatin versus sorafenib for intrahepatic advanced HCC us...

Full description

Bibliographic Details
Main Authors: Yuki Zaizen, Masahito Nakano, Kazuta Fukumori, Yoichi Yano, Kota Takaki, Takashi Niizeki, Kotaro Kuwaki, Masaru Fukahori, Takahiko Sakaue, Sohei Yoshimura, Mika Nakazaki, Ryoko Kuromatsu, Shusuke Okamura, Hideki Iwamoto, Shigeo Shimose, Tomotake Shirono, Yu Noda, Naoki Kamachi, Hironori Koga, Takuji Torimura
Format: Article
Language:English
Published: MDPI AG 2021-10-01
Series:Cancers
Subjects:
hepatocellular carcinoma
hepatic arterial infusion chemotherapy
cisplatin
sorafenib
multikinase inhibitor
risk factors
Online Access:https://www.mdpi.com/2072-6694/13/21/5282

Internet

https://www.mdpi.com/2072-6694/13/21/5282

Similar Items